{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:39:05Z","timestamp":1767847145056,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.schres.2003.06.001","type":"journal-article","created":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T10:56:24Z","timestamp":1068202584000},"page":"143-150","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia"],"prefix":"10.1016","volume":"66","author":[{"given":"Peter F.","family":"Buckley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin A.","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2003.06.001_BIB1","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV","author":"American Psychiatric Association","year":"1994"},{"issue":"4","key":"10.1016\/j.schres.2003.06.001_BIB2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2003.06.001_BIB3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2003.06.001_BIB4","series-title":"Schizophrenia","first-page":"489","article-title":"Treatment refractory schizophrenia","author":"Barnes","year":"2003"},{"issue":"4","key":"10.1016\/j.schres.2003.06.001_BIB5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group","volume":"155","author":"Bondolfi","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2003.06.001_BIB6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13651500050517849","article-title":"The long-term effect of quetiapine (\u2018Seroquel\u2019) monotherapy on weight in patients with schizophrenia","volume":"4","author":"Brecher","year":"2000","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2003.06.001_BIB7","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0006-3223(01)01256-2","article-title":"Broader therapeutic uses for atypical antipsychotic medications","author":"Buckley","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2003.06.001_BIB8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","article-title":"When symptoms persist: clozapine augmentation strategies","volume":"27","author":"Buckley","year":"2001","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2003.06.001_BIB9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2003.06.001_BIB10","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/S0924-977X(97)88647-6","article-title":"A long-term treatment with \u2018Seroquel\u2019 (quetiapine) in a severe schizophrenia patient","volume":"7","author":"Chinchilla","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2003.06.001_BIB11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","article-title":"Evaluation of treatment-resistant schizophrenia","volume":"23","author":"Conley","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2003.06.001_BIB12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2003.06.001_BIB13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-3223(99)00029-3","article-title":"Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response","volume":"46","author":"Conley","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2003.06.001_BIB14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","article-title":"A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, \u2018Seroquel\u2019) and haloperidol in schizophrenia","volume":"30","author":"Copolov","year":"2000","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.schres.2003.06.001_BIB33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0193-953X(02)00016-3","article-title":"The new and evolving pharmacotherapy of schizophrenia","volume":"26","author":"Emsley","year":"2003","journal-title":"Psychiatr. Clin. North Am."},{"issue":"3","key":"10.1016\/j.schres.2003.06.001_BIB15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200015030-00001","article-title":"A comparison of the effects of quetiapine (\u2018seroquel\u2019) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group","volume":"15","author":"Emsley","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2003.06.001_BIB16","series-title":"Neuropsychopharmacology: A Fifth Generation of Progress","article-title":"Parmacoeconomics of schizophrenia","author":"Essock","year":"2002"},{"issue":"1","key":"10.1016\/j.schres.2003.06.001_BIB17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2007-979291","article-title":"An open comparison of clozapine and risperidone in treatment-resistant schizophrenia","volume":"31","author":"Flynn","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.schres.2003.06.001_BIB18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2003.06.001_BIB19","unstructured":"Kane, J.M., 2003. Aripiprazole for treatment-refractory schizophrenia. Presentation at the Annual meeting of the American Psychiatric Association, San Fransico, May."},{"issue":"9","key":"10.1016\/j.schres.2003.06.001_BIB20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2003.06.001_BIB21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","article-title":"Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison","volume":"58","author":"Kane","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2003.06.001_BIB22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1517\/14656566.1.4.783","article-title":"Review of quetiapine and its clinical applications in schizophrenia","volume":"1","author":"Kasper","year":"2000","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1, Suppl. 1","key":"10.1016\/j.schres.2003.06.001_BIB23","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1097\/00004714-199502001-00008","article-title":"Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia","volume":"15","author":"Klieser","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 23","key":"10.1016\/j.schres.2003.06.001_BIB24","first-page":"13","article-title":"The efficacy of quetiapine in relieving persistent symptoms in a patient with poor response to both conventional and atypical antipsychotic therapy","volume":"60","author":"Koziupa","year":"1999","journal-title":"J. Clin. Psychol."},{"issue":"11","key":"10.1016\/j.schres.2003.06.001_BIB25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v58n1103","article-title":"Olanzapine in treatment-refractory schizophrenia: results of an open label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia","volume":"58","author":"Martin","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2003.06.001_BIB26","first-page":"242","article-title":"Varying definitions of treatment refractoriness and treatment response influence assessment of clinical value of clozapine","volume":"49","author":"Reese","year":"2001","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2003.06.001_BIB27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0920-9964(03)80222-0","article-title":"Clozapine and risperidone in moderately refractory schizophrenia: a six month double-blind comparison","volume":"60","author":"Schooler","year":"2003","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2003.06.001_BIB28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2003.06.001_BIB29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2003.06.001_BIB30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0920-9964(99)00154-1","article-title":"Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life","volume":"43","author":"Voruganti","year":"2000","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2003.06.001_BIB31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2003.06.001_BIB32","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996403002160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996403002160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T08:08:34Z","timestamp":1682582914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996403002160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":33,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0920996403002160"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2003.06.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}